Vanguard Group’s Harpoon Therapeutics, Inc. Common Stock HARP Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | – | Sell |
-880,017
| Closed | -$10M | – | 4555 |
|
|
2023
Q4 | $10M | Buy |
880,017
+766,655
| +676% | +$6.03M | ﹤0.01% | 2947 |
|
|
2023
Q3 | $457K | Sell |
113,362
-1,953
| -2% | -$14.5K | ﹤0.01% | 4077 |
|
|
2023
Q2 | $819K | Hold |
115,315
| – | – | ﹤0.01% | 3961 |
|
|
2023
Q1 | $858K | Hold |
115,315
| – | – | ﹤0.01% | 3969 |
|
|
2022
Q4 | $837K | Buy |
115,315
+52
| +0% | +$438 | ﹤0.01% | 3967 |
|
|
2022
Q3 | $1.12M | Sell |
115,263
-5,312
| -4% | -$99.1K | ﹤0.01% | 3970 |
|
|
2022
Q2 | $2.3M | Sell |
120,575
-8,245
| -6% | -$214K | ﹤0.01% | 3745 |
|
|
2022
Q1 | $6.4M | Buy |
128,820
+3,439
| +3% | +$178K | ﹤0.01% | 3399 |
|
|
2021
Q4 | $9.47M | Sell |
125,381
-3,237
| -3% | -$221K | ﹤0.01% | 3240 |
|
|
2021
Q3 | $10.2M | Buy |
128,618
+3,033
| +2% | +$305K | ﹤0.01% | 3235 |
|
|
2021
Q2 | $17.4M | Buy |
125,585
+6,772
| +6% | +$1.29M | ﹤0.01% | 2918 |
|
|
2021
Q1 | $24.9M | Buy |
118,813
+55,096
| +86% | +$11M | ﹤0.01% | 2669 |
|
|
2020
Q4 | $10.6M | Buy |
63,717
+7,489
| +13% | +$1.16M | ﹤0.01% | 2963 |
|
|
2020
Q3 | $9.55M | Buy |
56,228
+10,952
| +24% | +$1.58M | ﹤0.01% | 2813 |
|
|
2020
Q2 | $7.52M | Buy |
45,276
+4,919
| +12% | +$767K | ﹤0.01% | 2901 |
|
|
2020
Q1 | $4.67M | Buy |
40,357
+1,288
| +3% | +$181K | ﹤0.01% | 2996 |
|
|
2019
Q4 | $5.78M | Buy |
39,069
+174
| +0.4% | +$26.4K | ﹤0.01% | 3126 |
|
|
2019
Q3 | $5.31M | Buy |
38,895
+15,457
| +66% | +$2.17M | ﹤0.01% | 3120 |
|
|
2019
Q2 | $3.05M | Buy |
23,438
+15,165
| +183% | +$1.76M | ﹤0.01% | 3339 |
|
|
2019
Q1 | $783K | Buy |
+8,273
| New | +$1.09M | ﹤0.01% | 3691 |
|
Vanguard Group's HARP Position: Q1 2024 in Review
Vanguard Group sold out of Harpoon Therapeutics, Inc. Common Stock (HARP) in Q1 2024, closing a stake of 880,017 shares — an estimated $10M sold.
Vanguard Group first reported a position in HARP in Q1 2019 and held it in 20 quarters. The position peaked at $24.9M in Q1 2021. 0 funds tracked by Wall St. Rank hold HARP as of Q1 2024.
- Vanguard Group reported no remaining Harpoon Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
- Vanguard Group sold 880,017 Harpoon Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $10M.
- Vanguard Group first reported a position in Harpoon Therapeutics, Inc. Common Stock in Q1 2019 and held it in 20 quarters.
- Vanguard Group's Harpoon Therapeutics, Inc. Common Stock position peaked at $24.9M in Q1 2021.
- 0 funds tracked by Wall St. Rank held Harpoon Therapeutics, Inc. Common Stock as of Q1 2024.
Based on Vanguard Group's 13F filing for Q1 2024, filed 10 May 2024.